Clinical Trial News and Research

RSS

Phase I clinical trial: Sanaria PfSPZ Vaccine provides complete protection against malaria

Results of a phase I clinical trial of the Sanaria PfSPZ Vaccine to combat malaria, published today in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites. Plasmodium falciparum is the malaria parasite that causes more than 600,000 deaths annually.

9 Aug 2013

Investigational malaria vaccine offers protection against malaria infection in healthy adults

An investigational malaria vaccine has been found to be safe, to generate an immune system response, and to offer protection against malaria infection in healthy adults, according to the results of an early-stage clinical trial published Aug. 8 in the journal Science.

9 Aug 2013

Researchers develop first avatar-based decision support technology for caregivers

One of life's toughest decisions is whether to continue or withdraw life-sustaining therapies for loved ones who are unable to make their own healthcare decisions.

9 Aug 2013

One-third of patients with heart pumps develop infection at abdominal power connection site

Cardiac surgeons and cardiologists at the University of Maryland Heart Center are part of a multi-center clinical trial evaluating the efficacy of powering heart pumps through a skull-based connector behind the ear. Typically, these devices for patients with severe heart failure are energized through an electrical cord connected at an abdominal site, where potentially deadly infections can develop.

8 Aug 2013

UAH invents smart pill bottle that notifies you to take your medications

Patented at The University of Alabama in Huntsville, (UAH), a smart pill bottle that notifies you to take your medications or reminds you if you missed a dose could be en route to medicine cabinets as soon as 2015.

8 Aug 2013

Eteplirsen offers great hope to patients with Duchenne muscular dystrophy

Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health.

8 Aug 2013

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

An experimental drug designed to block the advance of type 1 diabetes in its earliest stages has proven strikingly effective over two years in about half of the patients who participated in the phase 2 clinical trial.

8 Aug 2013

Prolonged exposure therapy does not increase drinking in PTSD and alcohol dependent patients

Contrary to past concerns, using prolonged exposure therapy to treat patients with post-traumatic stress disorder (PTSD) and comorbid alcohol dependence does not increase drinking or cravings, Penn Medicine psychiatrists report in the August 7 issue of JAMA, a theme issue on violence/human rights.

7 Aug 2013

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Statins, a class of drugs used to lower cholesterol, are among the best selling drugs in North America and around the world. However, statin myopathy, which results in muscle pain and weakness, is a common side effect affecting up to 10 percent of statin users. A recent study led by Dr. Richard Kim of the Lawson Health Research Institute, in collaboration with Dr. Robert Hegele of Robarts Research Institute, and researchers from Vanderbilt University, found that commonly occurring genetic variations in a person's genes could put them at risk for statin-associated muscle injury.

7 Aug 2013

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone marrow that most often affects older adults. CLL responds to bone marrow stem cell transplantation (allo-HSCT); however, the rate of relapse for CLL remains relatively high.

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

HTR3 variants associated with effectiveness of ondansetron treatment for alcohol dependence

An experimental treatment for alcohol dependence works better in individuals who possess specific combinations of genes that regulate the function and binding of serotonin, a brain chemical affected by the treatment, according to a study supported by the National Institutes of Health. A report of the finding appears online in the American Journal of Psychiatry.

3 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

New survey commissioned by PhRMA identifies America's top health priorities

A new survey commissioned by the Pharmaceutical Research and Manufacturers of America shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities, followed by developing effective treatments for heart disease (78 percent) and more intensive medical care for seniors (76 percent).

2 Aug 2013

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.

2 Aug 2013

Boehringer Ingelheim, Lilly initiate linagliptin clinical trial in adults with Type 2 Diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced enrollment of the first patient into a cardiovascular and renal outcomes trial for linagliptin (Trajenta).

1 Aug 2013

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

Using the immune system to control cancer: an interview with Dr. Jedd Wolchok, MD, PhD, Ludwig Center at MSKCC

Cancer immunotherapy aims to recruit a patient’s immune system to recognize cancer as foreign and dangerous and to remove it from the body, as it would an infection.

1 Aug 2013

Intrinsic Therapeutics enrolls 400th patient in randomized clinical trial to evaluate effectiveness of Barricaid prosthesis

Intrinsic Therapeutics today announced the enrollment of the 400th patient in a level 1, prospective, randomized, multi-center clinical trial evaluating the effectiveness of its Barricaid Prosthesis in improving outcomes for lumbar discectomy patients suffering from sciatica.

1 Aug 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

Clinical Trial News and Research

Phase I clinical trial: Sanaria PfSPZ Vaccine provides complete protection against malaria

Investigational malaria vaccine offers protection against malaria infection in healthy adults

Researchers develop first avatar-based decision support technology for caregivers

One-third of patients with heart pumps develop infection at abdominal power connection site

UAH invents smart pill bottle that notifies you to take your medications

Eteplirsen offers great hope to patients with Duchenne muscular dystrophy

Teplizumab to block type 1 diabetes proves strikingly effective in phase 2 clinical trial

Prolonged exposure therapy does not increase drinking in PTSD and alcohol dependent patients

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Tumor cell vaccination has potential to enhance anti-tumor responses following allo-HSCT

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

HTR3 variants associated with effectiveness of ondansetron treatment for alcohol dependence

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

New survey commissioned by PhRMA identifies America's top health priorities

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

Boehringer Ingelheim, Lilly initiate linagliptin clinical trial in adults with Type 2 Diabetes

Viropharma announces financial results for second quarter of 2013

Using the immune system to control cancer: an interview with Dr. Jedd Wolchok, MD, PhD, Ludwig Center at MSKCC

Intrinsic Therapeutics enrolls 400th patient in randomized clinical trial to evaluate effectiveness of Barricaid prosthesis

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery